Exelixis Announces Webcasts of Investor Conference Presentations in March
07 March 2018 - 8:05AM
Business Wire
—Presentations to be webcast on
www.exelixis.com—
Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.
Morrissey, Ph.D., the company’s President and Chief Executive
Officer, will provide an overview of the company at the following
investor conferences in March:
- Cowen and Company 38th Annual Health
Care Conference: Exelixis is scheduled to present at 12:00 PM EDT /
9:00 AM PDT on Monday, March 12, 2018 in Boston.
- Barclays Capital Global Healthcare
Conference: Exelixis is scheduled to present at 11:15 AM EDT / 8:15
AM PDT on Tuesday, March 13, 2018 in Miami.
- Oppenheimer 28th Annual Healthcare
Conference: Exelixis is scheduled to present at 9:45 AM EDT / 6:45
AM PDT on Tuesday, March 20, 2018 in New York.
- Needham Healthcare Conference: Exelixis
is scheduled to present at 11:00 AM EDT / 8:00 AM PDT on Tuesday,
March 27, 2018 in New York.
To access the webcast links, log onto www.exelixis.com and
proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s
website at least 15 minutes prior to each presentation to ensure
adequate time for any software download that may be required to
listen to the webcasts. Replays will also be available at the same
location for 14 days.
About Exelixis
Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in
model genetic systems, we established a broad drug discovery and
development platform that has served as the foundation for our
continued efforts to bring new cancer therapies to patients in
need. We discovered our lead compounds, cabozantinib and
cobimetinib, and advanced them into clinical development before
entering into partnerships with leading biopharmaceutical companies
in our efforts to bring these medicines to patients globally. We
are steadfast in our commitment to prudently reinvest in our
business to maximize the potential of our pipeline. We intend to
supplement our existing therapeutic assets with targeted business
development activities and internal drug discovery – all to deliver
the next generation of Exelixis medicines and help patients recover
stronger and live longer. Exelixis recently earned a spot on
Deloitte’s Technology Fast 500 list, a yearly award program
honoring the 500 fastest-growing companies over the past four
years. For more information about Exelixis, please visit
www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis,
Inc. on Facebook.
Exelixis and the Exelixis logo are registered
U.S. trademarks.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180306006635/en/
Investors Contact:Exelixis, Inc.Susan Hubbard,
650-837-8194EVP, Public Affairs andInvestor
Relationsshubbard@exelixis.comorMedia Contact:For Exelixis,
Inc.Hal Mackins, 415-994-0040hal@torchcommunications.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Apr 2024 to May 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From May 2023 to May 2024